Strategic Expansion Cleerly is actively partnering with leading genetics firms like Allelica to deploy a polygenic risk score test for coronary artery disease, signaling a potential cross-selling path for genetic testing services, data integration, and collaboration on AI-driven risk assessment solutions.

AI Diagnostics The company focuses on AI-empowered non-invasive CT imaging and AI-QCT research, presenting opportunities to propose enterprise analytics deployments, workflow integration with radiology IT systems, and licensing or co-development of AI models for cardiovascular diagnostics.

Clinical Collaboration Participation in major cardiovascular imaging events (SCCT) and ongoing clinical research heritage indicate openings for partnerships with hospitals and health systems to deploy Cleerly’s phenotyping platform, expand pilot programs, and secure long-term contracts around CAD assessment.

Intellectual Property Recent patent-related litigation highlights the need for robust technology diligence and partner alignment; sales can focus on trusted services agreements, co-development arrangements, and clear IP ownership terms to reassure customers and investors.

Financial Scale With substantial funding and a mid-sized enterprise footprint, Cleerly targets mid-to-large health systems and payers for scalable implementations, offering enterprise licenses, service-based pricing, and data analytics partnerships to drive adoption and revenue growth.